Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
3.970
-0.020 (-0.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Autolus Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
August 08, 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 26, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
June 17, 2024
Via
Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
March 18, 2024
Via
Benzinga
Autolus Therapeutics's Earnings Outlook
March 13, 2024
Via
Benzinga
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
June 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
June 13, 2024
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
Via
InvestorPlace
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
May 31, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Crude Oil Gains 1%; GameStop Shares Plunge
May 17, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 17, 2024
Via
Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 17, 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
May 17, 2024
Via
Benzinga
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 17, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
May 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
May 13, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
April 24, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
April 11, 2024
Via
Benzinga
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
April 02, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
March 15, 2024
Via
Benzinga
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Blood Cancer Journal
March 11, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via
Benzinga
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
February 29, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications
February 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Announces Pricing of Underwritten Offering
February 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.